SpringWorks Therapeutics Inc (SWTX) - Total Liabilities
Based on the latest financial reports, SpringWorks Therapeutics Inc (SWTX) has total liabilities worth $87.96 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SWTX shareholders equity momentum to track the company's year-over-year net asset growth rate.
SpringWorks Therapeutics Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how SpringWorks Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of SpringWorks Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
SpringWorks Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of SpringWorks Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fluidra
MC:FDR
|
Spain | €2.06 Billion |
|
Selcuk Ecza Deposu Ticaret ve Sanayi AS
IS:SELEC
|
Turkey | TL50.95 Billion |
|
Financière Amuse TopCo SAS
ST:ASMDEE-B
|
Sweden | Skr1.39 Billion |
|
CCOOP Group Co Ltd
SHE:000564
|
China | CN¥16.68 Billion |
|
Yinyi Real Estate Co Ltd
SHE:000981
|
China | CN¥4.61 Billion |
|
Grupa KĘTY SA
WAR:KTY
|
Poland | zł2.69 Billion |
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
USA | $23.07 Billion |
|
IGO Ltd
AU:IGO
|
Australia | AU$239.10 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down SpringWorks Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SpringWorks Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SpringWorks Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SpringWorks Therapeutics Inc (2000–2024)
The table below shows the annual total liabilities of SpringWorks Therapeutics Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $106.17 Million | +6.63% |
| 2023-12-31 | $99.57 Million | +38.19% |
| 2022-12-31 | $72.05 Million | +139.38% |
| 2021-12-31 | $30.10 Million | +57.31% |
| 2020-12-31 | $19.13 Million | +49.96% |
| 2019-12-31 | $12.76 Million | -81.17% |
| 2018-12-31 | $67.76 Million | +413.05% |
| 2017-12-31 | $13.21 Million | -4.17% |
| 2010-12-31 | $13.78 Million | +17.21% |
| 2009-12-31 | $11.76 Million | -25.94% |
| 2008-12-31 | $15.88 Million | -22.83% |
| 2007-12-31 | $20.57 Million | -13.02% |
| 2006-12-31 | $23.66 Million | -0.20% |
| 2005-12-31 | $23.70 Million | -21.97% |
| 2004-12-31 | $30.37 Million | -24.07% |
| 2003-12-31 | $40.00 Million | +10.78% |
| 2002-12-31 | $36.11 Million | -22.69% |
| 2001-12-31 | $46.71 Million | -22.57% |
| 2000-12-31 | $60.32 Million | -- |
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more